Pfizer Snagged Another Approval for This Immunology Drug
Recently, the Food and Drug Administration (FDA) approved Pfizer's (NYSE: PFE) Xeljanz to treat adult patients with active ankylosing spondylitis who had failed to respond to at least one tumor necrosis factor (TNF) inhibitor, including AbbVie's (NYSE: ABBV) Humira. This came just weeks after the European Commission approved the drug for the same indication in the European Union.
Let's look at why the FDA authorized Xeljanz as a treatment for ankylosing spondylitis and what that means for pharma stock Pfizer.
Image source: Getty Images.
Source Fool.com
